Genelux (NASDAQ: GNLX) reported third quarter 2025 results and clinical updates on Nov 5, 2025. The company held $21.0 million in cash, cash equivalents, short-term investments and restricted cash as of Sept 30, 2025, which management expects will fund operations into the third quarter of 2026. Topline data from the OnPrime Phase 3 ovarian cancer registrational trial is now anticipated in the second half of 2026. Additional interim data from two systemically delivered Olvi-Vec lung cancer trials are expected in Q4 2025 and through 2026. Q3 2025 net loss was $8.0 million (loss per share $0.21); R&D was $4.7 million and G&A was $3.5 million.
Key program notes: OnPrime remains enrolling in the U.S.; the Independent Data Monitoring Committee has recommended continuation; company believes positive PFS without OS decrement could support traditional FDA approval based on a Type D meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.